NCT07598448Not yet recruitingNot Applicable
Clinical Experience With Iptacopan in Adult Patients With Complement 3 Glomerulopathy (C3G): A Multicenter, Observational, Retrospective Study of Patients Treated Through an Early Access Program in Spain
Trial Snapshot
- Phase
- Not Applicable
- Status
- Not yet recruiting
- Sponsor
- Novartis Pharmaceuticals
- Enrollment
- 35
Study Overview
Brief Summary
This study aims to characterize the patient profiles and the clinical experience of iptacopan treatment in adult patients with C3G treated through an early access program (EAP) in Spain.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Retrospective
Eligibility Criteria
- Ages
- 18 Years to 100 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Adult patients (≥18 years).
- •Biopsy-confirmed C3G.
- •Patients who have received at least one dose of iptacopan through an EAP from October 2020 to June 2025.
Exclusion Criteria
- •1. Patients treated with iptacopan through an EAP for indications other than C3G.
Arms & Interventions
Iptacopan Cohort
Adult patients with C3G who received iptacopan through an EAP in Spain.
Investigators
Similar Trials
Recruiting
Phase 3
Study to assess the pharmacokinetics, safety, and tolerability of iptacopan in pediatric PNH patients2024-515926-10-00Novartis Pharma AG5
Recruiting
Not Applicable
Safety and Efficacy of Iptacopan in Patients With High-Risk Transplantation-Associated Thrombotic MicroangiopathyThrombotic MicroangiopathyNCT07347990First Affiliated Hospital of Zhejiang University30
Recruiting
Phase 2
A randomized, controlled study to evaluate LNP023 (iptacopan) in patients with active ANCA-associated vasculitis.2023-510525-15-00Novartis Pharma AG44
Recruiting
Phase 4
A rollover extension program (REP) to evaluate the long-term safety and tolerability of open label iptacopan in adult participants with primary IgA nephropathy2023-508690-92-00Novartis Pharma AG100
Completed
Phase 3
A multicenter, single arm, open-label trial to evaluate efficacy and safety of oral, twice daily iptacopan in adult PNH patients who have Hb≥10 g/dL in response to anti-C5 antibody and switch to iptacopan2022-502148-10-00Novartis Pharma AG25